Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 177-182

  Minami Shimmyo, Yuko ^a   Ohe, Yuichiro ^a   Yamamoto, Seiichiro ^b   Sumi, Minako ^a   Nokihara, Hiroshi ^a   Horinouchi, Hidehito ^a   Yamamoto, Noboru ^a   Sekine, Ikuo ^a   Kubota, Kaoru ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Chemotherapy; Lung cancer; Risk factor; Thoracic radiotherapy; Treatment related death

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CAUSE OF DEATH; CHEMORADIOTHERAPY; DRUG FATALITY; EMPHYSEMA; FEMALE; HUMAN; HYPONATREMIA; HYPOXIA; LUNG CANCER; LUNG FIBROSIS; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; RADIATION PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SENESCENCE; SHOCK;

EID: 84655170202     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31823c4c07     Document Type: Article

References (16)

1. Ohe Y, Yamamoto S, Suzuki K, et al. Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 2001;37:54-63. (Pubitemid 32119360)
2. Morittu L, Earl HM, Souhami RL, et al. Patients at risk of chemotherapy- associated toxicity in small cell lung cancer. Br J Cancer 1989;59: 801-804. (Pubitemid 19148548)
3. Radford JA, Ryder WD, Dodwell D, et al. Predicting septic complications of chemotherapy:an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 1992;29A:81-86.
4. Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials: Can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer 1994;11: 259-274. (Pubitemid 24289178)
5. Sekine I, Noda K, Oshita F, et al. Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 2004;95:691-695. (Pubitemid 39255819)
6. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1999;45:323-329. (Pubitemid 29408545)
7. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18:317-323. (Pubitemid 46323100)
8. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20: 3054-3060. (Pubitemid 34791094)
9. Noda K, Nishiwaki Y, Kawahara M, et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. (Pubitemid 34438898)
10. Sekine I, Sumi M, Ito Y, et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol 2006;80:93-97. (Pubitemid 44226433)
11. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556. (Pubitemid 46630633)
12. Barlési F, Villani P, Doddoli C, et al. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004;18:85-91. (Pubitemid 38200923)
13. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000;89:1953-1960.
14. Schild SE, Stella PJ, Geyer SM, et al. North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III nonsmall- cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206. (Pubitemid 46606250)
15. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005;103:2349-2354. (Pubitemid 40686582)
16. Aupérin A, Le Péchoux C, Pignon JP, et al; Meta-Analysis of Cisplatin/ carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-483. (Pubitemid 43329586)